GSK’s strategic priorities
GSK has focused its business around the delivery of three strategic priorities, which aim to increase growth,
reduce risk and improve GSK’s long-term financial performance:
• Grow a diversified global business
• Deliver more products of value
• Simplify GSK’s operating model
Total Group turnover for Q3 2011 increased 3% to £7,104 million, with Pharmaceuticals and Vaccines turnover up 3% to £5,775 million (Pharmaceuticals up 1% to £4,633 million and Vaccines up 14% to £1,142 million). Consumer Healthcare sales increased 5% to £1,329 million.
GSK’s late-stage Pharmaceuticals and Vaccines pipeline
There were several news events for late-stage pipeline assets in this quarter and these are listed in the table
below. On the regulatory side, Horizant was filed with the FDA for post-herpetic neuralgia and GSK received a second complete response letter for Menhibrix. Also, data on IPX066 (Parkinson’s disease), Promacta in Hepatitis C and RTS,S were received in the quarter, and recruitment was completed in a variety of studies.
In February 2011, the following 15 assets were listed as expected to deliver Phase III data by the end of 2012: 1120212, 2118436, 2402968, 642444+573719, albiglutide, dolutegravir (1349572), IPX066, MAGE-A3 (event driven), migalastat HCl, RTS,S, otelixizumab, Promacta, Relovair, Tykerb, Votrient. Phase III data were announced from studies on IPX066, otelixizumab and Votrient in Q1 and Promacta and Relovair in Q2.
Data were announced in Q3 from the final pivotal study for IPX066, a head-to-head study versus Stalevo in
Parkinson’s disease (ASCEND). Additionally, the first data were announced from the Phase III study of Mosquirix for malaria prophylaxis in 5-17 month old children. Of the 15 assets with data expected by the end of 2012, six have now reported data. Of these, data have been filed for Votrient in sarcoma, data is in-house and being reviewed for Promacta (Hepatitis C) and IPX066 in Parkinson’s disease and programmes are ongoing for Relovair and RTS,S. One study, with otelixizumab, failed to show efficacy. Overall, by the end of 2012 GSK expects more than 30 further Phase III read-outs on the ongoing assets.
